Petaling Jaya

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer2 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial

Phase

• Phase 33 trials

Status

• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Olema Pharmaceuticals, Inc.2 trials
• Syndax Pharmaceuticals1 trial

Running trials

• Recruiting

  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  NCT07211958· Phase 3· Syndax Pharmaceuticals· Source

  Contact: Syndax Pharmaceuticals

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

  Contact: Olema Pharmaceuticals, Inc.

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• Metastatic breast cancer1 recruiting